缓解、黏膜愈合和需用结肠切除手术:高质量的研究证明英夫利昔单抗可有效诱导临床缓解,并促进黏膜愈合,对那些常规治疗难治性的中重度炎症性结肠炎患者,可在短期减少结肠切除术需求。而且现已证明,作为挽救治疗,可有效诱导缓解。在治疗中重度溃疡性结肠炎方面,比安慰剂更为有效。[56]D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn disease. Curr Gastroenterol Rep. 2006 Dec;8(6):506-12.http://www.ncbi.nlm.nih.gov/pubmed/17105690?tool=bestpractice.com[57]Lichtenstein GR, Abreu MT, Cohen R, et al; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar;130(3):935-9.https://www.gastrojournal.org/article/S0016-5085(06)00073-4/fulltexthttp://www.ncbi.nlm.nih.gov/pubmed/16530531?tool=bestpractice.com[58]Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005112.http://www.ncbi.nlm.nih.gov/pubmed/16856078?tool=bestpractice.com[59]Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am. 2006 Dec;35(4):821-36.http://www.ncbi.nlm.nih.gov/pubmed/17129815?tool=bestpractice.com[60]Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007 Jan 1;25(1):19-37.https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2006.03131.xhttp://www.ncbi.nlm.nih.gov/pubmed/17229218?tool=bestpractice.com[61]Wilhelm SM, McKenney KA, Rivait KN, et al. A review of infliximab use in ulcerative colitis. Clin Ther. 2008 Feb;30(2):223-30.http://www.ncbi.nlm.nih.gov/pubmed/18343261?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
缓解、黏膜愈合和需用结肠切除手术:高质量的研究证明英夫利昔单抗可有效诱导临床缓解,并促进黏膜愈合,对那些常规治疗难治性的中重度炎症性结肠炎患者,可在短期减少结肠切除术需求。而且现已证明,作为挽救治疗,可有效诱导缓解。在治疗中重度溃疡性结肠炎方面,比安慰剂更为有效。[56]D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn disease. Curr Gastroenterol Rep. 2006 Dec;8(6):506-12.http://www.ncbi.nlm.nih.gov/pubmed/17105690?tool=bestpractice.com[57]Lichtenstein GR, Abreu MT, Cohen R, et al; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar;130(3):935-9.https://www.gastrojournal.org/article/S0016-5085(06)00073-4/fulltexthttp://www.ncbi.nlm.nih.gov/pubmed/16530531?tool=bestpractice.com[58]Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005112.http://www.ncbi.nlm.nih.gov/pubmed/16856078?tool=bestpractice.com[59]Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am. 2006 Dec;35(4):821-36.http://www.ncbi.nlm.nih.gov/pubmed/17129815?tool=bestpractice.com[60]Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007 Jan 1;25(1):19-37.https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2006.03131.xhttp://www.ncbi.nlm.nih.gov/pubmed/17229218?tool=bestpractice.com[61]Wilhelm SM, McKenney KA, Rivait KN, et al. A review of infliximab use in ulcerative colitis. Clin Ther. 2008 Feb;30(2):223-30.http://www.ncbi.nlm.nih.gov/pubmed/18343261?tool=bestpractice.com